Abstract: Stabilized substituted benzimidazole modified release pharmaceutical formulations with at least two drug-containing fractions, wherein the release from a first fraction precedes the release from a second fraction, pharmaceutical excipients, processes for preparing the stable formulations, packaging therefor, and their use in treatment of erosive esophagitis and heartburn associated with non-erosive gastroesophageal reflux disease.

Abstract: Pharmaceutical formulations comprising inert cores that are coated with a layer comprising an amorphous dexlansoprazole sodium salt formed in-situ, further sequentially coated with an intermediate layer and an enteric coating layer. Coated cores may be further formulated to produce tablets or capsules.

Abstract: A process for preparing pure omeprazole Form B, and compositions containing omeprazole Form B.

Abstract: Stabilized desloratadine-containing pharmaceutical compositions are prepared using complexes formed by combining desloratadine and a resin in the acidic form.

Abstract: Pharmaceutical compositions comprising montelukast or pharmaceutically acceptable salts, solvates, polymorphs, enantiomers or mixtures thereof.

Abstract: Stable pharmaceutical compositions comprising zafirlukast and pharmaceutically acceptable salts, solvates, polymorphs, enantiomers or mixtures thereof, together with one or more pharmaceutically acceptable polymers, and processes for their preparation.

Abstract: Solid pharmaceutical compositions of valacyclovir or pharmaceutically acceptable salts thereof. Embodiments of the invention relate to processes for preparing solid pharmaceutical compositions, avoiding a wet granulation step.